ARCHIVES

Advisors Reaffirm Survival As Standard For full FDA Approval Of Cancer Drugs

This article is from The Cancer Letter archive.

Vol. 25 No. 24 | June 16, 1999

Download PDF Visit The Full Archive

Related Articles

Q&A: Data that Killed CYP2D6 Testing Contradict Fundamental Law of Nature

May 18, 2012

Cancer Center To Get Recommended Funding, Restoration of 1990-91 Cuts, NCI Tells Directors

July 24, 1992

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

March 28, 2014

CIDAC Bids Not Limited To Cancer Research Centers

January 17, 1975

Includes May issue of Business & Regulatory Report.

May 31, 2002

In Brief: NIH Intramural Research Said Needing Better Peer Review, Change In Selecting Counselors

April 23, 1976